An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate

Criteria

Inclusion Criteria:

• Retinitis Pigmentosa in both eyes

• Visual acuity between 20/40 to count fingers

Exclusion Criteria:

• Growth of new blood vessels in the eye

• Any intraocular surgery or laser in either eye in the last 6 months prior to Screening visit or between the Screening visit and Day 1

• Any ocular disease that can interfere with diagnosis and or assessment of disease progression

• Significant near-sightedness

• HIV

• Female patients who are pregnant, nursing, or planning pregnancy